ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Account Active
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / HSCS / options
LFWD (32) CUPR (21) CLGN (41) RGNT (31) ⌘ Pro Terminal β†’

HeartSciences Inc. (HSCS) Options Positioning, Max Pain & Unusual Sweeps

$2.99 -9.67% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.93

HeartSciences Inc. (HSCS) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $16.0M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HSCS Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is HSCS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, HeartSciences Inc. (NASDAQ: HSCS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.99 (-9.67% 1D, market cap $16.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, HSCS ranks #518 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does HSCS compare to LFWD and CUPR in the Health Care sector?
β–Ό

Within the Health Care sector (Industrial Specialties), HSCS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 59.1%, and ROIC of -35.0%. By comparison, LFWD (Lifeward Ltd.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $16.9M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, HSCS leads on earnings multiple (N/A) while HSCS leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HSCS?
β–Ό

Per HSCS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001468492), HeartSciences Inc. generated $4.3K in revenue (-0.7% YoY), -$9.1M in net income, and -$7.4M in free cash flow against $4.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.93 (-1.93%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (38/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510038
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D
Cash (7)Whales (9)SEC (8)Macro (11)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
$6 Bull$3 Base$2 Bear
πŸ“¬ FREE HSCS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for HSCS)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
πŸ” WHY HSCS SCORES 38/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+11/20 pts (29% of score)

FRED Regime Γ— Technicals: 38% of 52W Range β€’ RSI-14 at 47.8 (NEUTRAL RANGE)

β–² #2 Bullish Driver: Whale & Options Positioning+9/20 pts (24% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
46
Grade D$3.09+1.3% Next Q
Q2 (-2Q)
43
Grade D$3.13+4.8% Next Q
Q3 (-1Q)
41
Grade D$3.28-8.8% Next Q
Current
38
Grade D-$2.99-7.8% Hist 90D Ξ±
Trajectory: D (46) β†’ D- (38)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a HSCS Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While HSCS currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.63) and Max Pain ($3.14) forces dealer call-delta covering toward $5.51.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HSCSβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œHSCS Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (HSCS)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for HSCS.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HSCS)

  • βœ“Walkthrough of HSCS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
HSCS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +46.57%β–² ASCENDING CHANNEL
2026-11-03O $3.61H $3.61L $2.99C $2.99VOL 54.5K
RES: $6.00SUP: $2.21SMA50: $3.63SMA200: $2.72
$5.50$4.45$3.40$2.35$1.30RES $6.00SUP $2.21$2.992026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HSCS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ HSCS Butterfly Map β†’ + Track HSCS β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -0.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HSCS today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for HSCS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HSCS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HSCS)

Health Care Rank #518 of 1015 βš”οΈ LFWD vs HSCS Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (HSCS vs. LFWD, CUPR, CLGN, RGNT)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, HeartSciences Inc. (HSCS) ranks #518 by composite RQD confidence (38/100, grade D-) and #848 by equity capitalization ($16.0M). Within this direct 5-issuer industry benchmark cohort, HSCS leads on earnings valuation at N/A trailing P/E, while HSCS leads on capital efficiency and profitability with -35.0% ROIC and 59.1% gross margin. CLGN currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with HSCS at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
HSCS ACTIVE
HeartSciences Inc.
D- 38/100 β€” 59.1% -35.0% -9.67% $16.0M Benchmark Subject
LFWD
Lifeward Ltd.
E 32/100 β€” 96.0% -35.0% +1.82% $16.9M /lfwd-vs-hscs β†’
CUPR
Cuprina Holdings (Cayman) Limited (Class A)
E 21/100 β€” -1.3% -35.0% +3.96% $13.5M /cupr-vs-hscs β†’
CLGN
CollPlant Biotechnologies Ltd
D- 41/100 β€” 64.8% -35.0% -1.33% $11.9M /clgn-vs-hscs β†’
RGNT
Regentis Biomaterials Ltd.
E 31/100 β€” β€” -35.0% 0.00% $9.6M /rgnt-vs-hscs β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2026-04-30 β€’ CIK 0001468492 β†—

In its most recent audited fiscal period (FY2025, filed 2026-04-30), HeartSciences Inc. (HSCS) reported GAAP revenue of $4.3K (-0.7% vs. FY2024 revenue of $4.3K , and -76.8% cumulative change since FY2023) , GAAP net income of -$9.1M, operating cash flow of -$7.4M, and free cash flow of -$7.4M (-0.2% YoY). On the balance sheet, HSCS closed FY2025 with $4.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-04-30 $4.3K -$9.1M -$7.4M -$7.4M $4.2M β€”
FY2024 (FY) 2025-04-30 $4.3K -$8.8M -$7.4M -$7.4M $5.7M β€”
FY2023 (FY) 2024-04-30 $18.6K -$6.6M -$6.1M -$6.1M β€” β€”

3. HSCS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HSCS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, HeartSciences Inc. (NASDAQ: HSCS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.99 (-9.67% 1D, market cap $16.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, HSCS ranks #518 in composite RQD confidence.

How does HSCS compare to LFWD and CUPR in the Health Care sector?

Within the Health Care sector (Industrial Specialties), HSCS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 59.1%, and ROIC of -35.0%. By comparison, LFWD (Lifeward Ltd.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $16.9M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M). Among the 5-stock peer group, HSCS leads on earnings multiple (N/A) while HSCS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HSCS?

Per HSCS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001468492), HeartSciences Inc. generated $4.3K in revenue (-0.7% YoY), -$9.1M in net income, and -$7.4M in free cash flow against $4.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HSCS trading relative to its 50-day, 200-day, and 52-week technical levels?

HSCS last traded at $2.99 (-9.67% on volume of 69,925 shares), positioning the stock -17.63% below its 50-day simple moving average ($3.63) and +9.93% above its 200-day simple moving average ($2.72). Across its 52-week range of $1.63 to $5.25, HSCS sits at the 37.6% percentile with a 14-day RSI of 47.8 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($2.62 to $3.36).

Direct Sub-Reports: HSCS RQD Cockpit HSCS 12M Forecast HSCS Earnings & Move HSCS Dividends & DRIP HSCS Insiders & 13F HSCS Whale Options HSCS Profit Sankey HSCS News & Why
ROARABLE RATING BRIEF β€’ RQD 38/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

HSCS β€” HeartSciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-04-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

HeartSciences Inc. (HSCS) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.99 (-9.67% 1D, market capitalization $16.0M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 59.1%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

HeartSciences Inc. Is a NASDAQ-listed company classified under the Health Care sector and the Industrial Specialties industry. Reported revenue is β€” across the periods provided, with gross margin listed at 59.1%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-04-30), HeartSciences Inc. (HSCS) reported $4.3K in annual revenue (up from $4.3K in FY2024, -0.7% YoY) and -$9.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($18.6K revenue, -$6.6M net income) through FY2025, HSCS scaled operating cash flow to -$7.4M and free cash flow to -$7.4M, backed by $4.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 9/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $1.63 – $5.25 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be mapped from the source data. Sector correlation beyond the stated beta of 1. The principal second-order exposure a prospective investor should monitor is the pending business combination, since headlines link HSCS to a counterparty in a different sector, and the outcome of that transaction could reshape the company's identity and capital structure.

  • Key Question #1: Can HSCS sustain or expand its -60.0% operating margin and -35.0% ROIC against Industrial Specialties peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $4.3K and free cash flow of -$7.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is HSCS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

HSCS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for HeartSciences Inc. (HSCS) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to HSCS Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HSCS Bull vs. Bear Conversation Board β€” What's Your Call at $2.99?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HSCS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on HSCS:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER β€’ Swing & Catalyst Trader πŸ‚ BULLISH 🎯 Target: $3.97 (+19.9%)
πŸ“Œ Pinned Debate

The pending business combination with Fortitude Mining could reshape the company's capital base and listing profile.

Long HSCS at $3.31 targeting $3.97. The pending business combination with Fortitude Mining could reshape the company's capital base and listing profile.. Institutional whale score is 9/20 and the risk/reward vs. the $1.63 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader πŸ‚ BULL

@MeanReversion_88 Shorting a 9/20 institutional whale-flow stock at $3.31 is dangerous when funds are rotating into Health Care.

ME MeanReversion_88 RQD DEBATE OPENER β€’ Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $2.65 (-19.9%)
Spot @ $3.31

Negative ROIC of -35%, zero FCF yield, and cash falling to $1.1M against a $7.4M annual FCF outflow signal near-term funding strain.

I respect the product at HeartSciences Inc., but the stock at $3.31 is a different story. Negative ROIC of -35%, zero FCF yield, and cash falling to $1.1M against a $7.4M annual FCF outflow signal near-term funding strain.. FCF yield is 0.0% and RQD sits at 38/100 (D-) β€” why pay up here when you can wait for next quarter's numbers?

LIVE TAPE